$KRYS
Krystal Biotech, Inc.

2022 Q4 Form 10-Q Financial Statement

#000171127922000058 Filed on November 07, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.03M $19.94M
YoY Change 86.76% 108.26%
% of Gross Profit
Research & Development $10.74M $11.52M
YoY Change 19.23% 89.41%
% of Gross Profit
Depreciation & Amortization $1.089M $669.0K
YoY Change 38.9% 41.14%
% of Gross Profit
Operating Expenses $34.77M $31.45M
YoY Change 58.95% 100.94%
Operating Profit -$31.45M
YoY Change 100.94%
Interest Expense $2.719M $0.00
YoY Change 3784.29%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$32.05M -$29.85M
YoY Change 46.99% 91.48%
Income Tax
% Of Pretax Income
Net Earnings -$32.05M -$29.85M
YoY Change 46.99% 91.48%
Net Earnings / Revenue
Basic Earnings Per Share -$1.17
Diluted Earnings Per Share -$1.25 -$1.17
COMMON SHARES
Basic Shares Outstanding 25.75M shares 25.66M shares
Diluted Shares Outstanding 25.62M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $379.2M $394.4M
YoY Change -13.45% 14.96%
Cash & Equivalents $161.9M $186.4M
Short-Term Investments $217.3M $208.0M
Other Short-Term Assets $4.608M $3.158M
YoY Change 10.48% 16.15%
Inventory $0.00
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $383.8M $397.6M
YoY Change -13.22% 14.97%
LONG-TERM ASSETS
Property, Plant & Equipment $161.7M $157.8M
YoY Change 43.9% 100.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $4.621M $12.56M
YoY Change -92.82% -34.72%
Other Assets $324.0K $205.0K
YoY Change 337.84% 230.65%
Total Long-Term Assets $174.7M $178.8M
YoY Change -5.08% 69.83%
TOTAL ASSETS
Total Short-Term Assets $383.8M $397.6M
Total Long-Term Assets $174.7M $178.8M
Total Assets $558.5M $576.4M
YoY Change -10.83% 27.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.981M $5.761M
YoY Change -52.6% 21.11%
Accrued Expenses $24.56M $21.68M
YoY Change 43.03% -30.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $28.85M $28.03M
YoY Change 12.09% -21.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.372M $7.575M
YoY Change 5.57% 7.01%
Total Long-Term Liabilities $7.372M $7.575M
YoY Change 5.57% 7.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.85M $28.03M
Total Long-Term Liabilities $7.372M $7.575M
Total Liabilities $36.22M $35.61M
YoY Change 10.7% -16.92%
SHAREHOLDERS EQUITY
Retained Earnings -$280.8M -$248.7M
YoY Change 99.45% 108.99%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $522.2M $540.8M
YoY Change
Total Liabilities & Shareholders Equity $558.5M $576.4M
YoY Change -10.83% 27.77%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$32.05M -$29.85M
YoY Change 46.99% 91.48%
Depreciation, Depletion And Amortization $1.089M $669.0K
YoY Change 38.9% 41.14%
Cash From Operating Activities -$22.33M -$19.69M
YoY Change 6.84% 171.37%
INVESTING ACTIVITIES
Capital Expenditures $5.217M -$14.06M
YoY Change -112.76% -33.04%
Acquisitions
YoY Change
Other Investing Activities $9.000K -$687.0K
YoY Change -100.01% -95.75%
Cash From Investing Activities -$5.208M -$14.74M
YoY Change -95.88% -60.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.069M 2.120M
YoY Change -98.48% 40.58%
NET CHANGE
Cash From Operating Activities -22.33M -19.69M
Cash From Investing Activities -5.208M -14.74M
Cash From Financing Activities 3.069M 2.120M
Net Change In Cash -24.47M -32.31M
YoY Change -144.79% -24.71%
FREE CASH FLOW
Cash From Operating Activities -$22.33M -$19.69M
Capital Expenditures $5.217M -$14.06M
Free Cash Flow -$27.55M -$5.632M
YoY Change -237.85% -141.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001711279
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38210
dei Entity Registrant Name
EntityRegistrantName
Krystal Biotech, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1080209
dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Wharton Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 701
dei Entity Address City Or Town
EntityAddressCityOrTown
Pittsburgh
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
15203
dei City Area Code
CityAreaCode
412
dei Local Phone Number
LocalPhoneNumber
586-5830
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
KRYS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25747647 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186409000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
341246000 usd
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
208011000 usd
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
96850000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3158000 usd
krys Cumulative Escalation Clause Term
CumulativeEscalationClauseTerm
P5Y
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4171000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
397578000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
442267000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
157786000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112355000 usd
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
12557000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
64371000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8253000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7228000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
205000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74000 usd
CY2022Q3 us-gaap Assets
Assets
576379000 usd
CY2021Q4 us-gaap Assets
Assets
626295000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5761000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8398000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1547000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1041000 usd
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
20724000 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
16297000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
28032000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25736000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7575000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6983000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
35607000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
32719000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2061773 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2061773 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25709664 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25709664 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25207985 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25207985 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
790954000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
734523000 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1475000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-163000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248707000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-140784000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
540772000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
593576000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
576379000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
626295000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11516000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6080000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31720000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18875000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19935000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9572000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
53705000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27524000 usd
CY2022Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
CY2021Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
25000000 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
31451000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15652000 usd
us-gaap Operating Expenses
OperatingExpenses
110425000 usd
us-gaap Operating Expenses
OperatingExpenses
46399000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31451000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15652000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-110425000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-46399000 usd
CY2022Q3 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
1601000 usd
CY2021Q3 krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
63000 usd
krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
2502000 usd
krys Interest Income Expense And Other Nonoperating Net
InterestIncomeExpenseAndOtherNonoperatingNet
127000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
0 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
1492000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29850000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15589000 usd
us-gaap Net Income Loss
NetIncomeLoss
-107923000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47764000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
70000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1312000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-20000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29780000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15582000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-109235000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47784000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.18
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25619125 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25619125 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22212266 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22212266 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25428097 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25428097 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21893656 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21893656 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3565110 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
593576000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
55000 usd
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
649000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6571000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1034000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-49965000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
548554000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30748000 usd
CY2022Q2 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
7500 shares
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8335000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-348000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28108000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
559181000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2176000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9195000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
70000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29850000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
540772000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
292084000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
152033000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2350000 usd
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-15812000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
430652000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4261000 usd
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16363000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
418540000 usd
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1534000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3745000 usd
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15589000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
408237000 usd
us-gaap Net Income Loss
NetIncomeLoss
-107923000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47764000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2966000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1985000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23678000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10174000 usd
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-22000 usd
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
0 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
0 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
1492000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-224000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-224000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1031000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1038000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1900638 shares
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
31000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
krys Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-459000 usd
krys Increase Decrease In Lease Liability
IncreaseDecreaseInLeaseLiability
-240000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-316000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-225000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3016000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6726000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78240000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27038000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27038000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47762000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
27453000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
214712000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
83810000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
153599000 usd
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
11033000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108875000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100230000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32927000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
153573000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
649000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
krys Payments For Suit Liability
PaymentsForSuitLiability
0 usd
krys Payments For Suit Liability
PaymentsForSuitLiability
7960000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32278000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
145613000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-154837000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18345000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
341246000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
268269000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186409000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
286614000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15305000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
23213000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1556000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4396000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-248700000 usd
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
394400000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-29850000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15589000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas including stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, and the valuation allowance included in the deferred income tax calculation.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the condensed consolidated balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
us-gaap Net Income Loss
NetIncomeLoss
-107923000 usd
us-gaap Net Income Loss
NetIncomeLoss
-47764000 usd
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25619125 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25619125 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22212266 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22212266 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25428097 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25428097 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21893656 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21893656 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.24
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.18
CY2022Q3 krys Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost
CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
408425000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
38000 usd
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1486000 usd
CY2022Q3 krys Cash Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsAndDebtSecuritiesAvailableForSale
406977000 usd
CY2021Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost
CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost
502636000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000 usd
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
180000 usd
CY2021Q4 krys Cash Cash Equivalents And Debt Securities Available For Sale
CashCashEquivalentsAndDebtSecuritiesAvailableForSale
502467000 usd
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
163587000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
116569000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5801000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4214000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
157786000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
112355000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
669000 usd
us-gaap Depreciation
Depreciation
1600000 usd
CY2021Q3 us-gaap Depreciation
Depreciation
474000 usd
us-gaap Depreciation
Depreciation
1400000 usd
CY2022Q3 krys Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
10905000 usd
CY2021Q4 krys Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
9606000 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2960000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2011000 usd
CY2022Q3 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
3934000 usd
CY2021Q4 krys Accrued Payroll And Benefits
AccruedPayrollAndBenefits
2882000 usd
CY2022Q3 krys Accrued Preclinical And Clinical Expenses
AccruedPreclinicalAndClinicalExpenses
2325000 usd
CY2021Q4 krys Accrued Preclinical And Clinical Expenses
AccruedPreclinicalAndClinicalExpenses
1602000 usd
CY2022Q3 krys Accrued Financing Fees Current
AccruedFinancingFeesCurrent
10000 usd
CY2021Q4 krys Accrued Financing Fees Current
AccruedFinancingFeesCurrent
26000 usd
CY2022Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
122000 usd
CY2021Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
83000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
468000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
87000 usd
CY2022Q3 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
20724000 usd
CY2021Q4 krys Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16297000 usd
CY2020Q4 krys Purchase Price Of Potential Building Purchase
PurchasePriceOfPotentialBuildingPurchase
9400000 usd
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
10000000 usd
CY2020Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
10000000 usd
CY2020Q4 krys Payment To Escrow For Reducing Lease Rentals
PaymentToEscrowForReducingLeaseRentals
2400000 usd
CY2020Q4 krys Purchase Price Of Potential Building Purchase
PurchasePriceOfPotentialBuildingPurchase
9400000 usd
CY2020Q4 us-gaap Escrow Deposit
EscrowDeposit
1500000 usd
krys Lessor Operating Lease Liability Annual Lease Payments
LessorOperatingLeaseLiabilityAnnualLeasePayments
82000 usd
krys Cumulative Escalation Clause Percent
CumulativeEscalationClausePercent
0.10
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
404000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1640000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1539000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1277000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1277000 usd
CY2022Q3 krys Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
12062000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18199000 usd
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9077000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
9122000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8253000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7228000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1547000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1041000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7575000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6983000 usd
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
9122000 usd
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
8024000 usd
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y7M6D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14Y4M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.095
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
399000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
339000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1200000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
836000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
48000 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
65000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
168000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
183000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
447000 usd
CY2021Q3 us-gaap Lease Cost
LeaseCost
404000 usd
us-gaap Lease Cost
LeaseCost
1368000 usd
us-gaap Lease Cost
LeaseCost
1019000 usd
CY2021Q3 krys Loss Contingency Guaranteed Maximum Price To Be Paid
LossContingencyGuaranteedMaximumPriceToBePaid
84100000 usd
CY2022Q3 us-gaap Proceeds From Insurance Settlement Operating Activities
ProceedsFromInsuranceSettlementOperatingActivities
0 usd
us-gaap Proceeds From Insurance Settlement Operating Activities
ProceedsFromInsuranceSettlementOperatingActivities
768000 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
372000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
412892 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
58.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
5001 shares
CY2021Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
227000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
198000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2043179 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
57.00
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
31331000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1958000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
63.03
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
84776 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
46.28
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
78.19
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3498510 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
60.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37213000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
637315 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
48.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14225000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1300000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2100000 usd
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
64000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
872000 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
137000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
423000 usd
CY2021Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
79000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
182000 usd

Files In Submission

Name View Source Status
0001711279-22-000058-index-headers.html Edgar Link pending
0001711279-22-000058-index.html Edgar Link pending
0001711279-22-000058.txt Edgar Link pending
0001711279-22-000058-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
krys-20220930.htm Edgar Link pending
krys-20220930.xsd Edgar Link pending
krys-20220930ex311.htm Edgar Link pending
krys-20220930ex312.htm Edgar Link pending
krys-20220930ex321.htm Edgar Link pending
krys-20220930_g1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
krys-20220930_def.xml Edgar Link unprocessable
krys-20220930_lab.xml Edgar Link unprocessable
krys-20220930_pre.xml Edgar Link unprocessable
krys-20220930_cal.xml Edgar Link unprocessable
krys-20220930_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending